516 related articles for article (PubMed ID: 15249498)
1. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
Collet JP; Montalescot G; Golmard JL; Tanguy ML; Ankri A; Choussat R; Beygui F; Drobinski G; Vignolles N; Thomas D
Am Heart J; 2004 Apr; 147(4):655-61. PubMed ID: 15077081
[TBL] [Abstract][Full Text] [Related]
3. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
[TBL] [Abstract][Full Text] [Related]
4. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.
Simoons ML; Bobbink IW; Boland J; Gardien M; Klootwijk P; Lensing AW; Ruzyllo W; Umans VA; Vahanian A; Van De Werf F; Zeymer U;
J Am Coll Cardiol; 2004 Jun; 43(12):2183-90. PubMed ID: 15193678
[TBL] [Abstract][Full Text] [Related]
5. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
[TBL] [Abstract][Full Text] [Related]
6. Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin.
Ramos-Esquivel A; Salazar-Sánchez L
Thromb Res; 2013 Oct; 132(4):433-6. PubMed ID: 24050826
[TBL] [Abstract][Full Text] [Related]
7. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
[TBL] [Abstract][Full Text] [Related]
8. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction.
Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Wienbergen H; Zahn R; Senges J
Thromb Haemost; 2008 Jan; 99(1):150-4. PubMed ID: 18217147
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
; Yusuf S; Mehta SR; Chrolavicius S; Afzal R; Pogue J; Granger CB; Budaj A; Peters RJ; Bassand JP; Wallentin L; Joyner C; Fox KA
N Engl J Med; 2006 Apr; 354(14):1464-76. PubMed ID: 16537663
[TBL] [Abstract][Full Text] [Related]
11. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
Hammerstingl C; Omran H; Tripp C; Poetzsch B
Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
[TBL] [Abstract][Full Text] [Related]
12. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
Zalc S; Lemos PA; Esteves A; Ribeiro EE; Horta P; Nicolau JC; Ramires JA; Cohen M; Martinez EE
J Invasive Cardiol; 2006 Feb; 18(2):45-8. PubMed ID: 16446514
[TBL] [Abstract][Full Text] [Related]
13. Enoxaparin in acute coronary syndromes.
Lee S; Gibson CM
Expert Rev Cardiovasc Ther; 2007 May; 5(3):387-99. PubMed ID: 17489664
[TBL] [Abstract][Full Text] [Related]
14. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.
Morrow DA; Antman EM; Snapinn SM; McCabe CH; Theroux P; Braunwald E
Eur Heart J; 2002 Feb; 23(3):223-9. PubMed ID: 11792137
[TBL] [Abstract][Full Text] [Related]
15. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention.
Chen WH; Lau CP; Lau YK; Ng W; Lee PY; Yu CM; Ma E
J Invasive Cardiol; 2002 Aug; 14(8):439-42. PubMed ID: 12147872
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
[TBL] [Abstract][Full Text] [Related]
17. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
Ma JM; Jackevicius CA; Yeo E
Ann Pharmacother; 2004 Oct; 38(10):1576-81. PubMed ID: 15328396
[TBL] [Abstract][Full Text] [Related]
18. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.
Collet JP; Montalescot G; Fine E; Golmard JL; Dalby M; Choussat R; Ankri A; Dumaine R; Lesty C; Vignolles N; Thomas D
J Am Coll Cardiol; 2003 Jan; 41(1):8-14. PubMed ID: 12570937
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
[TBL] [Abstract][Full Text] [Related]
20. Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial.
Cantor WJ; Goodman SG; Cannon CP; Murphy SA; Charlesworth A; Braunwauld E; Langer A
Am Heart J; 2005 Feb; 149(2):275-83. PubMed ID: 15846265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]